CoChat

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Open access

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

T-cell–mediated approaches have shown promise in myeloma treatment. However, there are currently a limited number of specific myeloma antigens that can be targeted, and multiple myeloma (MM) remains an incurable disease. G-protein–coupled receptor class 5 member D (GPRC5D) is expressed in MM and smoldering MM patient plasma cells. Here, we demonstrate that GPRC5D protein is present on the surface of MM cells and describe JNJ-64407564, a GPRC5DxCD3 bispecific antibody that recruits CD3+ T cells to GPRC5D+ MM cells and induces killing of GPRC5D+ cells. In vitro, JNJ-64407564 induced specific cytotoxicity of GPRC5D+ cells with concomitant T-cell activation and also killed plasma cells in MM patient samples ex vivo. JNJ-64407564 can recruit T cells and induce tumor regression in GPRC5D+ MM murine models, which coincide with T-cell infiltration at the tumor site. This antibody is also able to induce cytotoxicity of patient primary MM cells from bone marrow, which is the natural site of this disease. GPRC5D is a promising surface antigen for MM immunotherapy, and JNJ-64407564 is currently being evaluated in a phase 1 clinical trial in patients with relapsed or refractory MM (NCT03399799).

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.2019003342

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 174

Metadata

Authors
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., Chin, D., Luistro, L., Joseph, J., Chu, G., Packman, K., Shetty, S., Elsayed, Y., Attar, R., & Gaudet, F.
Affiliations
  • Janssen Research & Development (United States) (US)
  • Janssen Biotherapeutics and
  • Janssen Biotherapeutics, Janssen Research & Development, LLC, La Jolla, CA; and
Venue
Blood
Published
2020-04-09
Volume
135
Issue
15
Pages
1232-1243
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3005994291
Cited by
174
References
26
Citations by year
2026: 21 · 2025: 25 · 2024: 41 · 2023: 34 · 2022: 18 · 2021: 21 · 2020: 12
FWCI
13.41
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, GPRC5D, bispecific antibodies, CD3, T cell redirection, T cell cytotoxicity, T cell activation, plasma cells, smoldering multiple myeloma, relapsed/refractory multiple myeloma, tumor regression, T cell infiltration
MeSH terms
Antineoplastic Agents, Immunological, Animals, Cytotoxicity, Immunologic, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Multiple Myeloma, T-Lymphocytes, Antibodies, Bispecific, Receptors, G-Protein-Coupled, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.2019003342
The paper
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., Chin, D., Luistro, L., Joseph, J., Chu, G., Packman, K., Shetty, S., Elsayed, Y., Attar, R., & Gaudet, F. (2020). A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. https://doi.org/10.1182/blood.2019003342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.